Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health (BHC) and Prevent Blindness are launching a year-long video series during AMD Awareness Month to raise awareness about Age-Related Macular Degeneration (AMD), affecting around 16 million Americans. This marks the sixth consecutive year of their collaboration. The campaign will feature real-life stories of individuals managing AMD and will include a social media donation initiative, contributing $1 for each share or like on relevant Facebook posts, up to $50,000. The initiative aims to educate the public on AMD while encouraging eye examinations.

Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its fourth-quarter and full-year 2020 financial results on February 24, 2021. The company will hold a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can access the call through the company's Investor Relations section on its website, where all related materials will be available prior to the call.

Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), announced on January 21, 2021, that its LUMIFY® redness reliever eye drops received approval from South Korea's Ministry of Food and Drug Safety. This adds to LUMIFY's global presence, following its success in the U.S. where it holds a 40% market share among redness relievers. LUMIFY is expected to be available in South Korea in the second half of 2021, with additional regulatory submissions ongoing in multiple countries.

Bausch + Lomb announced that it will present data on its Bausch + Lomb INFUSE silicone hydrogel daily disposable contact lenses at the virtual Global Specialty Lens Symposium from Jan. 21-23, 2021. During this event, Bausch + Lomb will also discuss fitting efficiencies for its Zenlens™ scleral lenses. A survey reported that 97% of patients experienced crisp, clear vision with INFUSE lenses, and 94% agreed they help maintain moisture. Two poster presentations will focus on the lenses' impact on tear film protein and water stability.

Bausch Health announced the publication of a Phase 2 study in Cornea, demonstrating that NOV03, an investigational treatment for Dry Eye Disease (DED) related to Meibomian gland dysfunction, met its primary efficacy endpoint. The study enrolled 336 patients and exhibited significant improvements in corneal staining and symptoms like dryness and burning. Additionally, the first of two Phase 3 studies evaluating NOV03 has been fully enrolled with 599 participants. These developments position NOV03 as a potential first-in-class treatment for millions suffering from symptomatic DED.

Bausch Health Companies Inc. (BHC) is set to provide a preliminary update on Q4 and full-year 2020 financial results during a chat at the J.P. Morgan Healthcare Conference on Jan. 13, 2021. The company anticipates Q4 revenue exceeding $2.20 billion and full-year revenue surpassing $8.00 billion. Bausch Health projects over $1 billion in operational cash flow for 2020 and highlights a $900 million debt repayment. Full financial results will be released next month.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. ET. A live webcast and audio archive will be accessible on the company's Investor Relations page. Bausch Health focuses on improving lives through a range of healthcare products, primarily in eye health, gastroenterology, and dermatology. More details are available on their website.

Bausch Health Companies (NYSE/TSX: BHC) announced a new indication for DEXAVEN (dexamethasone phosphate) solution for injection in Poland. This approval allows treatment for COVID-19 in adults and adolescents who require oxygen therapy. The corticosteroid DEXAVEN helps reduce inflammation. CEO Thomas J. Appio expressed satisfaction with this development as it provides additional treatment options for patients. However, it is important to note that dexamethasone products are not FDA-approved for COVID-19 treatments in the United States.

Bausch Health announced plans to repay approximately $900 million of debt in 2020, including $275 million on Dec. 31, 2020. This repayment will leave the company with no debt maturities or mandatory amortization payments until 2024. Bausch Health's total debt repayment for the fourth quarter of 2020 will be around $480 million, reflecting strong cash flow recovery despite COVID-19's impacts. CEO Joseph C. Papa emphasized the commercial team's resilience and effective cash conservation strategies.